We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.